Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview - PubMed (original) (raw)

Review

. 2019 Oct;27(10):3729-3737.

doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30.

Daniel L Hertz 3, Manuel Morales 4, Elizabeth J Adams 5, Sharon Gordon 6 7, Chia Jie Tan 1 2, Nathan P Staff 8, Jayesh Kamath 9, Jeong Oh 10, Shivani Shinde 11 12, Doreen Pon 13, Niharkia Dixit 14 15, James D'Olimpio 16 17, Cristina Dumitrescu 18, Margherita Gobbo 19, Kord Kober 14 20, Samantha Mayo 21, Linda Pang 10, Ishwaria Subbiah 10, Andreas S Beutler 8, Katherine B Peters 22, Charles Loprinzi 8, Maryam B Lustberg 23

Affiliations

Review

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

Alexandre Chan et al. Support Care Cancer. 2019 Oct.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

Keywords: CIPN; Chemotherapy-induced peripheral neuropathy; Neuropathy.

PubMed Disclaimer

Figures

Figure 1:

Figure 1:. Molecular Targets and Pathways of CIPN

Affected neurons: dorsal root ganglion (∗); sensory neurons (∇); motor neurons (⊕); central projections of primary afferent neurons (σ). Abbreviations: VDAC – voltage-dependent anion channels; Ca2+ - calcium ions; TRP – transient receptor potential.

References

    1. Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013;21(7):2059–2066. -PMC -PubMed
    1. Miaskowski C, Mastick J, Paul SM, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv. 2018;12(2):234–245. -PMC -PubMed
    1. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. -PubMed
    1. Molassiotis A, Cheng HL, Leung KT, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019:e01312. -PMC -PubMed
    1. Bulls HW, Hoogland AI, Kennedy B, et al. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol. 2019;152(2):310–315. -PMC -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources